|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lozano R, Naghavi M, Foreman K, et al:
Global and regional mortality from 235 causes of death for 20 age
groups in 1990 and 2010: A systematic analysis for the Global
Burden of Disease Study 2010. Lancet. 380:2095–2128. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Devesa SS, Bray F, Vizcaino AP and Parkin
DM: International lung cancer trends by histologic type:
Male:female differences diminishing and adenocarcinoma rates
rising. Int J Cancer. 117:294–299. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
NSCLC Meta-analyses Collaborative Group.
Arriagada R, Auperin A, Burdett S, et al: Adjuvant chemotherapy,
with or without postoperative radiotherapy, in operable
non-small-cell lung cancer: Two meta-analyses of individual patient
data. Lancet. 375:1267–1277. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pignon JP, Tribodet H, Scagliotti GV, et
al: LACE Collaborative Group: Lung adjuvant cisplatin evaluation: A
pooled analysis by the LACE Collaborative Group. J Clin Oncol.
26:3552–3559. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reck M, Heigener DF, Mok T, Soria JC and
Rabe KF: Management of non-small-cell lung cancer: recent
developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Olaussen KA, Dunant A, Fouret P, et al:
IALT Bio Investigators: DNA repair by ERCC1 in non-small-cell lung
cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med.
355:983–991. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vilmar A and Sørensen JB: Excision repair
cross-complementation group 1 (ERCC1) in platinum-based treatment
of non-small cell lung cancer with special emphasis on carboplatin:
A review of current literature. Lung Cancer. 64:131–139. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reed E: Platinum-DNA adduct, nucleotide
excision repair and platinum based anti-cancer chemotherapy. Cancer
Treat Rev. 24:331–344. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Simon GR, Ismail-Khan R and Bepler G:
Nuclear excision repair-based personalized therapy for non-small
cell lung cancer: From hypothesis to reality. Int J Biochem Cell
Biol. 39:1318–1328. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Quinn JE, James CR, Stewart GE, et al:
BRCA1 mRNA expression levels predict for overall survival in
ovarian cancer after chemotherapy. Clin Cancer Res. 13:7413–7420.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Taron M, Rosell R, Felip E, et al: BRCA1
mRNA expression levels as an indicator of chemoresistance in lung
cancer. Hum Mol Genet. 13:2443–2449. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mann GJ, Musgrove EA, Fox RM and Thelander
L: Ribonucleotide reductase M1 subunit in cellular proliferation,
quiescence, and differentiation. Cancer Res. 48:5151–5156.
1988.PubMed/NCBI
|
|
14
|
Engström Y, Eriksson S, Jildevik I, Skog
S, Thelander L and Tribukait B: Cell cycle-dependent expression of
mammalian ribonucleotide reductase. Differential regulation of the
two subunits. J Biol Chem. 260:9114–9116. 1985.PubMed/NCBI
|
|
15
|
Jordan MA, Toso RJ, Thrower D and Wilson
L: Mechanism of mitotic block and inhibition of cell proliferation
by taxol at low concentrations. Proc Natl Acad Sci USA.
90:9552–9556. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sève P, Isaac S, Trédan O, et al:
Expression of class III β-tubulin is predictive of patient outcome
in patients with non-small cell lung cancer receiving
vinorelbine-based chemotherapy. Clin Cancer Res. 11:5481–5486.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bepler G, Williams C, Schell MJ, et al:
Randomized international phase III trial of ERCC1 and RRM1
expression-based chemotherapy versus gemcitabine/carboplatin in
advanced non-small-cell lung cancer. J Clin Oncol. 31:2404–2412.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tiseo M, Bordi P, Bortesi B, Boni C, et
al: Bio-FAST trial group: ERCC1/BRCA1 expression and gene
polymorphisms as prognostic and predictive factors in advanced
NSCLC treated with or without cisplatin. Br J Cancer.
108:1695–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Booton R, Ward T, Ashcroft L, Morris J,
Heighway J and Thatcher N: ERCC1 mRNA expression is not associated
with response and survival after platinum-based chemotherapy
regimens in advanced non-small cell lung cancer. J Thorac Oncol.
2:902–906. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cobo M, Isla D, Massuti B, et al:
Customizing cisplatin based on quantitative excision repair
cross-complementing 1 mRNA expression: A phase III trial in
non-small-cell lung cancer. J Clin Oncol. 25:2747–2754. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sobin LH, Gospodarowicz MK and Wittekind
C: Lung and Pleural Tumors. TNM Classification of Malignant Tumors
(7th). (Hoboken, NJ). Wiley-Blackwell. 136–148. 2010.
|
|
22
|
Arriagada R, Bergman B, Dunant A, Le
Chevalier T, Pignon JP and Vansteenkiste J: International Adjuvant
Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant
chemotherapy in patients with completely resected non-small-cell
lung cancer. N Engl J Med. 350:351–360. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Douillard JY, Rosell R, De Lena M, et al:
Adjuvant vinorelbine plus cisplatin versus observation in patients
with completely resected stage IB-IIIA non-small-cell lung cancer
(Adjuvant Navelbine International Trialist Association [ANITA]): A
randomised controlled trial. Lancet Oncol. 7:719–727. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mu D, Hsu DS and Sancar A: Reaction
mechanism of human DNA repair excision nuclease. J Biol Chem.
271:8285–8294. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zamble DB, Mu D, Reardon JT, Sancar A and
Lippard SJ: Repair of cisplatin - DNA adducts by the mammalian
excision nuclease. Biochemistry. 35:10004–10013. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
De Silva IU, McHugh PJ, Clingen PH and
Hartley JA: Defining the roles of nucleotide excision repair and
recombination in the repair of DNA interstrand cross-links in
mammalian cells. Mol Cell Biol. 20:7980–7990. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lian S, Su H, Zhao BX, Liu WY, Zheng LW
and Miao JY: Synthesis and discovery of pyrazole-5-carbohydrazide
N-glycosides as inducer of autophagy in A549 lung cancer cells.
Bioorg Med Chem. 17:7085–7092. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Holm B, Mellemgaard A, Skov T and Skov BG:
Different impact of excision repair cross-complementation group 1
on survival in male and female patients with inoperable
non-small-cell lung cancer treated with carboplatin and
gemcitabine. J Clin Oncol. 27:4254–4259. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee SH, Noh KB, Lee JS, et al: Thymidylate
synthase and ERCC1 as predictive markers in patients with pulmonary
adenocarcinoma treated with pemetrexed and cisplatin. Lung Cancer.
81:102–108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lord RV, Brabender J, Gandara D, et al:
Low ERCC1 expression correlates with prolonged survival after
cisplatin plus gemcitabine chemotherapy in non-small cell lung
cancer. Clin Cancer Res. 8:2286–2291. 2002.PubMed/NCBI
|
|
31
|
Zheng Z, Chen T, Li X, Haura E, Sharma A
and Bepler G: DNA synthesis and repair genes RRM1 and ERCC1 in lung
cancer. N Engl J Med. 356:800–808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Friboulet L, Olaussen KA, Pignon JP, et
al: ERCC1 isoform expression and DNA repair in non-small-cell lung
cancer. N Engl J Med. 368:1101–1110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee KH, Min HS, Han SW, et al: ERCC1
expression by immunohistochemistry and EGFR mutations in resected
non-small cell lung cancer. Lung Cancer. 60:401–407. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Harkin DP, Bean JM, Miklos D, et al:
Induction of GADD45 and JNK/SAPK-dependent apoptosis following
inducible expression of BRCA1. Cell. 97:575–586. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Potapova O, Haghighi A, Bost F, et al: The
Jun kinase/stress-activated protein kinase pathway functions to
regulate DNA repair and inhibition of the pathway sensitizes tumor
cells to cisplatin. J Biol Chem. 272:14041–14044. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pitterle DM, Kim YC, Jolicoeur EM, Cao Y,
O'Briant KC and Bepler G: Lung cancer and the human gene for
ribonucleotide reductase subunit M1 (RRM1). Mamm Genome.
10:916–922. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rosell R, Danenberg KD, Alberola V, et al:
Spanish Lung Cancer Group: Ribonucleotide reductase messenger RNA
expression and survival in gemcitabine/cisplatin-treated advanced
non-small cell lung cancer patients. Clin Cancer Res. 10:1318–1325.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Koh Y, Jang B, Han SW, et al: Expression
of class III beta-tubulin correlates with unfavorable survival
outcome in patients with resected non-small cell lung cancer. J
Thorac Oncol. 5:320–325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Burkhart CA, Kavallaris M and Band Horwitz
S: The role of β-tubulin isotypes in resistance to antimitotic
drugs. Biochim Biophys Acta. 1471:O1–O9. 2001.PubMed/NCBI
|
|
40
|
Gan PP, Pasquier E and Kavallaris M: Class
III β-tubulin mediates sensitivity to chemotherapeutic drugs in non
small cell lung cancer. Cancer Res. 67:9356–9363. 2007. View Article : Google Scholar : PubMed/NCBI
|
